BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38229249)

  • 1. Immune checkpoint inhibitor-related myasthenia gravis, myositis and myocarditis: a triad but not at the same time?
    Cooksley T; Weaver J; McNamara M; Lorigan P
    QJM; 2024 Jun; 117(5):373-374. PubMed ID: 38229249
    [No Abstract]   [Full Text] [Related]  

  • 2. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome.
    Lipe DN; Galvis-Carvajal E; Rajha E; Wechsler AH; Gaeta S
    Am J Emerg Med; 2021 Aug; 46():51-55. PubMed ID: 33721590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System.
    Niimura T; Zamami Y; Miyata K; Mikami T; Asada M; Fukushima K; Yoshino M; Mitsuboshi S; Okada N; Hamano H; Sakurada T; Matsuoka-Ando R; Aizawa F; Yagi K; Goda M; Chuma M; Koyama T; Izawa-Ishizawa Y; Yanagawa H; Fujino H; Yamanishi Y; Ishizawa K
    J Clin Pharmacol; 2023 Apr; 63(4):473-479. PubMed ID: 36453166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
    Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
    Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series.
    Weaver JM; Dodd K; Knight T; Chaudhri M; Khera R; Lilleker JB; Roberts M; Lorigan P; Cooksley T
    Support Care Cancer; 2023 Aug; 31(9):518. PubMed ID: 37572133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases.
    Pathak R; Katel A; Massarelli E; Villaflor VM; Sun V; Salgia R
    Oncologist; 2021 Dec; 26(12):1052-1061. PubMed ID: 34378270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Aldrich J; Pundole X; Tummala S; Palaskas N; Andersen CR; Shoukier M; Abdel-Wahab N; Deswal A; Suarez-Almazor ME
    Arthritis Rheumatol; 2021 May; 73(5):866-874. PubMed ID: 33258544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myasthenia gravis, myositis and myocarditis: a fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment.
    Soman B; Dias MC; Rizvi SAJ; Kardos A
    BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593626
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review.
    Wai Siu DH; O'Neill RS; Harris CA; Wang J; Ardolino L; Downton T; Tong M; Hong JH; Chin V; Clingan PR; Aghmesheh M; Soudy H
    Immunotherapy; 2022 May; 14(7):511-520. PubMed ID: 35321560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single-center case series.
    Longinow J; Zmaili M; Skoza W; Kondoleon N; Marquardt R; Calabrese C; Funchain P; Moudgil R
    Cancer Med; 2023 Feb; 12(3):2281-2289. PubMed ID: 36128926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous development of myasthenia gravis and myositis following treatment with pembrolizumab: a case report.
    Kiaei B; Chaudhry M; Banerjee S; Brewer J; Chen Y; Khasiyev F; Guzman MA; Hayat G
    BMC Neurol; 2024 Jun; 24(1):184. PubMed ID: 38824498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune checkpoint inhibitors induced side effects of the peripheral nervous system.
    Hundsberger T; Schreiner B; Roth P
    Curr Opin Neurol; 2023 Oct; 36(5):427-431. PubMed ID: 37639489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report.
    Cham J; Ng D; Nicholson L
    J Med Case Rep; 2021 May; 15(1):278. PubMed ID: 34053457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease.
    Leaver PJ; Jang HS; Vernon ST; Fernando SL
    BMJ Case Rep; 2020 May; 13(5):. PubMed ID: 32404371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies.
    Fazal M; Prentice DA; Kho LK; Fysh E
    Intern Med J; 2020 Aug; 50(8):1003-1006. PubMed ID: 33306231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms.
    Rhee JY; Torun N; Neilan TG; Guidon AC
    Oncologist; 2022 May; 27(5):e402-e405. PubMed ID: 35348772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan.
    Suzuki S; Ishikawa N; Konoeda F; Seki N; Fukushima S; Takahashi K; Uhara H; Hasegawa Y; Inomata S; Otani Y; Yokota K; Hirose T; Tanaka R; Suzuki N; Matsui M
    Neurology; 2017 Sep; 89(11):1127-1134. PubMed ID: 28821685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitor-Induced Myocarditis With Concurrent Myasthenia Gravis.
    Kuniyoshi J; Huang R; Choi H; Bernas M; Techasatian W; Nishimura Y
    Can J Cardiol; 2023 Nov; 39(11):1646-1648. PubMed ID: 37330137
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitor-Associated Myositis: A Distinct Form of Inflammatory Myopathy.
    Saygin D; Ghosh N; Reid P
    J Clin Rheumatol; 2022 Oct; 28(7):367-373. PubMed ID: 35696731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibition-Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade.
    Nelke C; Pawlitzki M; Kerkhoff R; Schroeter CB; Aktas O; Neuen-Jacob E; Polzin A; Meuth SG; Ruck T
    Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):. PubMed ID: 37884388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.